On Friday, Aphria reported its Q1, 2017 results. The licensed medical marijuana producer earned $895,269 on revenue of $4.37-million. The numbers were a solid beat over the same period a year earlier when it lost $476,825 on a topline of $950,740.
“Aphria continues to deliver on all operating metrics,” said CEO Vic Neufeld of the quarter. “Patient onboarding, harvest yields, delivering in-demand strains, kilograms sold and low production costs have again generated stellar top-line and bottom-line results. Completion of the part II expansion remains on schedule. Part III expansion just kicked off in the last two weeks. With expected annualized yields increasing to 18,000 kg upon completion of the expansions, Aphria is strategically positioned for continued sustainable growth.”
Zandberg notes that the results from Aphria bested his expectations of $0.01 a share in earnings and EBITDA of $1.0-million on revenue of $3.3-million. The analyst says the beat was likely due to the fact that Aphria has become the seller of choice for other licensed producers.
“Grams of MMJ sold during the quarter were 585,200 –we had modelled 408,480 grams,” notes the analyst. “The average selling price per gram was $7.48, slightlv lower than the price of $8.16 reported in Q4 FY16 (ending Mav 31). The reason for the lower average selling price per gram reported this quarter is likelv due to strong wholesale business. Aphria sells to other licensed producers at a wholesale price of $3.75 – $4.25. The wholesale business was particularlv strong during Q1 as several LPs had demand that exceeded internal production.”
In a research update to clients Friday, Zandberg maintained his “Buy” rating on Aphria but raised his one-year price target on the stock from $3.75 to $4.25. He pegs the risk level at “Speculative”.)
Zandberg believes Aphria will post net income of $4.24-million on revenue of $23.48-million in fiscal 2017, numbers he expects will climb to net income of $7.8-million on a topline of $43.41-million the following year.
Shares of APH closed Friday up 7.8 per cent to $3.58.
It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]
Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]
Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]
Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his "Buy" rating on Nova Leap Health (Nova Leap… [Read More]
The stock has been flat since November, but Citi analyst Tyler Radke thinks there is now money to be made… [Read More]
Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]
View Comments
Good to see a cannabis company grow like this. We need to legalize this
medicine already though!!